LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Aandelen Lijst・Fate Therapeutics Inc

Fate Therapeutics Inc

Gesloten

SectorGezondheidszorg

1.48 -5.73

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.45

Max

1.49

Belangrijke statistieken
By Trading Economics
Inkomsten	1.8M -32M
Verkoop	-166K 1.7M
Winstmarge	-1,852.384
Werknemers	181
EBITDA	7.9M -29M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+220.95% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	48M 174M
Vorige openingsprijs	7.21
Vorige sluitingsprijs	1.48

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.9101 / 1.14 Steun & Weerstand

Fate Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 feb 2026, 23:53 UTC

Populaire aandelen

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 feb 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28 feb 2026, 21:36 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 15:20 UTC

Winsten

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 feb 2026, 14:43 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 14:38 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 feb 2026, 13:47 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 13:44 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 feb 2026, 13:14 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 02:32 UTC

Winsten

Acquisities, Fusies, Overnames

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 feb 2026, 02:00 UTC

Acquisities, Fusies, Overnames

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 feb 2026, 02:00 UTC

Acquisities, Fusies, Overnames

Six Months, 9 Offers and $81 Billion. How -2-

28 feb 2026, 00:01 UTC

Acquisities, Fusies, Overnames

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 feb 2026, 23:46 UTC

Acquisities, Fusies, Overnames

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 feb 2026, 23:33 UTC

Acquisities, Fusies, Overnames

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 feb 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

27 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

27 feb 2026, 21:30 UTC

Winsten

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 feb 2026, 21:30 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 feb 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 feb 2026, 21:17 UTC

Winsten

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 21:10 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 feb 2026, 21:09 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 feb 2026, 21:00 UTC

Winsten

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 feb 2026, 20:31 UTC

Acquisities, Fusies, Overnames

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 feb 2026, 20:24 UTC

Marktinformatie

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 feb 2026, 20:23 UTC

Marktinformatie

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 feb 2026, 20:12 UTC

Marktinformatie

Nike Seen With Further Challenges in China -- Market Talk

27 feb 2026, 19:44 UTC

Marktinformatie

Gold Caps Historic Month -- Market Talk

27 feb 2026, 19:39 UTC

Winsten

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Fate Therapeutics Inc Prognose

Koersdoel

By TipRanks

220.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.75 USD 220.95%

Hoogste 7 USD

Laagste 2.5 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fate Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Fate Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.9101 / 1.14Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.